Skip to main content
. 2017 Jan-Feb;11(1-2):16–23. doi: 10.5489/cuaj.4303

Fig. 3.

Fig. 3.

Three-cell-type model demonstrating importance of low testosterone in intermittent androgen-deprivation therapy. Adapted from Klotz L, Toren P. Androgen deprivation therapy in advanced prostate cancer: Is intermittent therapy the new standard of care? Curr Oncol 2012;19:S13–21. Copyright 2012 by Multimed Inc. Adapted with permission.